Fri, Apr 18, 2014, 8:05 PM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

TaxuCardium Pharmaceuticals Group Inc. Message Board

ada95_lovelace 14 posts  |  Last Activity: Apr 10, 2014 9:47 AM Member since: Aug 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Someone wants shares

    by slavarus45 Apr 10, 2014 9:38 AM
    ada95_lovelace ada95_lovelace Apr 10, 2014 9:47 AM Flag

    Does that make you ameritrash piece of #$%$?

  • Reply to

    Ram Power ??

    by parto3frp Apr 1, 2014 2:34 PM
    ada95_lovelace ada95_lovelace Apr 7, 2014 9:01 AM Flag

    Great out of the box thinking! Congrats parto!

  • ada95_lovelace by ada95_lovelace Mar 27, 2014 7:39 AM Flag

    Looking again at these numbers I can not help but think the company is (deliberately)being modest with future full year guidance. If or when performance exceeds expectations once again, the bigger the blast.

  • Reply to

    Canaccord Genuity Rogues.

    by parto3frp Mar 27, 2014 4:32 AM
    ada95_lovelace ada95_lovelace Mar 27, 2014 6:54 AM Flag

    "...While U.S. Geothermal is advancing its development pipeline, we are not confident that these projects will ultimately be constructed. In our view, we cannot justify a premium multiple of this magnitude without a clear path to significant cash flow growth," added the analyst."

    Wow this company posts profits, give guidance and lays out a future growth path on both El S. and Guatemala and all this analyst can say is 'we are not confident' LOOOOL

    These profits won't go away unless a major fall out happens so until then HTM has a solid income from already 3 power plants with PPA's in place for 25 years.
    And all this guy can say is 'nah not good enough for us, you should take profits here' LOL

    You know what... I want that guys pay check cause I can do his job much much better!!!!

  • Reply to

    Think about it for a minute

    by worlds_8_wonder Mar 26, 2014 6:26 PM
    ada95_lovelace ada95_lovelace Mar 27, 2014 6:44 AM Flag

    Couldn't agree more! Da big boyzzz ran over the little men once again.
    This will reverse back up sooner than we think imo

  • Reply to

    Canaccord Genuity Rogues.

    by parto3frp Mar 27, 2014 4:32 AM
    ada95_lovelace ada95_lovelace Mar 27, 2014 6:39 AM Flag

    It's total BS and everyone who read the faux article knows it. It was deliberately written to create PANIC and to make people sell so that da big boyz. could scoop up more shares. And the selling hit stop losses... etc. etc.

  • Reply to

    Can someone enlighten me?

    by edmann63 Mar 26, 2014 11:50 AM
    ada95_lovelace ada95_lovelace Mar 26, 2014 12:03 PM Flag

    You are right, it might not be sexy. But it WILL grow and get larger and reach more people and bring in more cash. That is how a 'start up' company works.
    Hey! They deserve a some credit here, look at the 10k and check out the numbers. Afterall they have managed to turn the corner to profitabilty. This is a REAL company with REAL cash.

  • Reply to

    Can someone enlighten me?

    by edmann63 Mar 26, 2014 11:50 AM
    ada95_lovelace ada95_lovelace Mar 26, 2014 11:53 AM Flag

    This is what happens when the herd takes their money and let shorters take over AGAIN!
    This is called stupidity

  • ada95_lovelace by ada95_lovelace Mar 26, 2014 11:07 AM Flag

    Wow, they must have some news to to reveal. call has started!

  • ada95_lovelace ada95_lovelace Mar 26, 2014 9:45 AM Flag

    You can sell, that's the typcial herd mentality. Like everyone sold yesterday before earnings, that is also herd mentality. This is going up because the fundamentals are in place, cash is rolling in, power sites are full running and the company is expanding. What more do you need

  • Reply to

    Fins are out.

    by robtmsstt22 Mar 20, 2014 8:03 AM
    ada95_lovelace ada95_lovelace Mar 20, 2014 8:36 AM Flag

    yes, looks good

    "We are pleased with the increase in our ResponseDX(R) fourth quarter revenues growing by more than 25% over the third quarter and our gross margin increasing to 48%, all while we were investing in new marketing and sales initiatives and infrastructure for expected growth," said Thomas A. Bologna, the Company's Chairman & Chief Executive Officer.

    Mr. Bologna added, "We are optimistic and expect our first quarter and full year 2014 ResponseDX unit volume to increase nicely as a result of the initiatives we took in 2013, including our TC/PC program and the introduction of several new tests, but that is just part of our reason for optimism. We are particularly excited about our ResponseDX: Tissue of OriginTM test which we recently launched. We acquired that test when we purchased the assets of Pathwork Diagnostics in August of last year. The expansion of our Los Angeles facility to accommodate that purchase has been completed and today we have the test set-up and running. Additionally, in February our sales team was trained on the ResponseDX: Tissue of OriginTM test and today we are actively selling the test and processing orders."

  • Reply to

    MSTX Acquires Aires Pharmaceuticals, Inc

    by ada95_lovelace Feb 10, 2014 8:07 AM
    ada95_lovelace ada95_lovelace Feb 10, 2014 8:08 AM Flag

    We are paying significantly less than that to acquire the program and we currently estimate that our development costs for AIR001 for the first 12 months will be approximately $2million. Our estimated costs for AIR001 will change as we refine our development strategy over the next few months, but Aires is expected to contribute approximately $3 million of net cash at the closing of the merger, so, as currently contemplated, our first year of development of AIR001 will not require additional capital investment by Mast," Mr. Culley concluded.

    Under the terms of the all-stock transaction, Aires would become a wholly-owned subsidiary of Mast Therapeutics, Inc. in exchange for shares of Mast common stock representing approximately 6% of Mast's outstanding common stock, 80% of which would be subject to a six-month holdback for certain indemnification claims of Mast. There are no milestone obligations payable to Aires. The acquisition is expected to close in February 2014 , subject to customary closing conditions.

    About AIR001 AIR001 (sodium nitrite) inhalation solution, also known as Aironite, is an intermittently nebulized formulation of nitrite. Under hypoxic conditions, AIR001 is converted to nitric oxide. Nitrite mediated nitric oxide formation has several beneficial effects, including dilation of blood vessels and reduction of inflammation and undesirable cell growth.

    AIR001 has been granted orphan drug status by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.

  • SAN DIEGO , Feb. 10, 2014 /PRNewswire/ -- Mast Therapeutics, Inc . (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.

    "The acquisition of Aires will enhance our pipeline with a phase 2 asset with more than 120 human subject exposures and which is a strategic complement to our lead program, MST-188. With total consideration of approximately 6% of Mast equity, it represents excellent value for our stockholders," stated Brian M. Culley , Chief Executive Officer of Mast Therapeutics, Inc.

    "Nitrite has demonstrable beneficial properties, including vasodilation and the reduction of inflammation and undesirable cell growth.These are important therapeutic objectives and an ideal complement to MST-188 and its ability to improve blood flow and seal cellular membranes. In addition, we intend to investigate the hypothesis that AIR001 positively affects mitochondrial activity and myocyte energetics. With this acquisition, and the initiation of our phase 2 trial of MST-188 for the treatment of acute limb ischemia later this quarter, we are taking additional steps towards building a sustainable company with a valuable pipeline addressing significant unmet needs in both specialized and major markets," Mr. Culley continued.

    "Another highlight of this acquisition is its favorable economics. Aires had completed several venture financings, including a $20 million Series B round. We are paying significantly less than that to acquire the program and we currently estimate

  • Reply to

    PPS predictions by the end of March, 2014?

    by brendan_morris43 Jan 30, 2014 12:07 PM
    ada95_lovelace ada95_lovelace Jan 30, 2014 12:29 PM Flag

    $2.90

CRXM
0.51-0.01(-1.92%)Apr 17 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT